{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T04:15:11Z","timestamp":1754194511873,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T00:00:00Z","timestamp":1517788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11239-018-1624-3","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T07:30:50Z","timestamp":1517815850000},"page":"588-592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5888-3585","authenticated-orcid":false,"given":"Sergio","family":"Fasullo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Dav\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gioacchino","family":"Cosenza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Di Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"La Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Giubilato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziella","family":"Vetrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Maringhini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,5]]},"reference":[{"issue":"22","key":"1624_CR1","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","volume":"61","author":"TB Larsen","year":"2013","unstructured":"Larsen TB, Rasmussen LH, Skj\u00f8th F et al (2013) Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61(22):2264\u20132273","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1624_CR2","first-page":"1277","volume":"114","author":"JD1 Seeger","year":"2015","unstructured":"Seeger JD1, Bykov K, Bartels D et al (2015) Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 114(6):1277\u20131289","journal-title":"Thromb Haemost"},{"key":"1624_CR3","unstructured":"Pradaxa and Agranulocytosis\u2014from FDA reports as at Jan 2018; \n                    https:\/\/www.ehealthme.com\/ds\/pradaxa\/agranulocytosis\/"},{"key":"1624_CR4","unstructured":"EMA\u2014European database of suspected adverse drug reaction reports, as at Jan 2018; \n                    https:\/\/bi.ema.europa.eu\/analyticsSOAP\/saw.dll?PortalPages"},{"key":"1624_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2165\/00003495-197815020-00003","volume":"15","author":"V Pisciotta","year":"1978","unstructured":"Pisciotta V (1978) Drug-induced agranulocytosis. Drugs 15:132\u2013143","journal-title":"Drugs"},{"issue":"6","key":"1624_CR6","first-page":"1116","volume":"103","author":"J Ryn Van","year":"2011","unstructured":"Van Ryn J, Stangier J, Haertter S et al (2011) Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116\u20131127","journal-title":"Thromb Haemost"},{"issue":"5","key":"1624_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","volume":"47","author":"J Stangier","year":"2008","unstructured":"Stangier J (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47(5):285\u2013295","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1624_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/dmd.107.019083","volume":"36","author":"S Blech","year":"2008","unstructured":"Blech S, Ebner T, Ludwig-Schwellinger E et al (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36(2):386\u2013399","journal-title":"Drug Metab Dispos"},{"key":"1624_CR9","unstructured":"Pradaxa (2001) Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT; \n                    http:\/\/www.accessdata.fda.gov\/ drugsatfda_docs\/label\/2011\/022512s004lbl.pdf"},{"key":"1624_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ejim.2006.07.012","volume":"17","author":"E Andr\u00e8s","year":"2006","unstructured":"Andr\u00e8s E, Zimmer J, Affenberger S et al (2006) Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur J Intern Med 17:529\u2013535","journal-title":"Eur J Intern Med"},{"key":"1624_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","volume":"146","author":"F Andersohn","year":"2007","unstructured":"Andersohn F, Konzen C, Garbe E (2007) Nonchemotherapy drug-induced agranulocytosis: a systematic review of case reports. Ann Intern Med 146:657\u2013665","journal-title":"Ann Intern Med"},{"issue":"1","key":"1624_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","volume":"15","author":"E Andr\u00e8s","year":"2008","unstructured":"Andr\u00e8s E, Maloisel F (2008) Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 15(1):15\u201321","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"1624_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ajh.21433","volume":"84","author":"D Tesfa","year":"2009","unstructured":"Tesfa D, Keisu M, Palmblad J (2009) Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 84(7):428\u2013434","journal-title":"Am J Hematol"},{"key":"1624_CR14","first-page":"279","volume":"10","author":"AV Pisciotta","year":"1973","unstructured":"Pisciotta AV (1973) Immune and toxic mechanisms in drug-induced agranulocytosis. Semin Hematol 10:279\u2013310","journal-title":"Semin Hematol"},{"key":"1624_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2141.1989.tb07672.x","volume":"72","author":"A Salama","year":"1989","unstructured":"Salama A, Schutz B, Kiefel V et al (1989) Immune-mediated agranulocytosis related to drugs and their metabolites:mode of sensitization and heterogeneity of antibodies. Br J Haematol 72:127\u2013132","journal-title":"Br J Haematol"},{"key":"1624_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","volume":"146","author":"F Andersohn","year":"2007","unstructured":"Andersohn F, Konzen C, Garbe E (2007) Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146:657\u2013665","journal-title":"Ann Intern Med"},{"key":"1624_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151","journal-title":"N Engl J Med"},{"key":"1624_CR18","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","volume":"123","author":"GJ Hankey","year":"2001","unstructured":"Hankey GJ, Eikelboom JW (2001) Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 123:1436\u20131450","journal-title":"Circulation"},{"key":"1624_CR19","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2169\/internalmedicine.51.7601","volume":"51","author":"H Hayashi","year":"2012","unstructured":"Hayashi H, Kitoh K, Mitsunami K et al (2012) Agranulocytosis immediately oral admistraion cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation. Intern Med 51:1987\u20131990","journal-title":"Intern Med"},{"issue":"8","key":"1624_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archinte.165.8.869","volume":"165","author":"L Ib\u00e1\u00f1ez","year":"2005","unstructured":"Ib\u00e1\u00f1ez L, Vidal X, Ballar\u00edn E et al (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165(8):869\u2013874","journal-title":"Arch Intern Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1624-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1624-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1624-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T19:20:23Z","timestamp":1549308023000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1624-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,5]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1624-3","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2018,2,5]]},"assertion":[{"value":"5 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}